BMP type i receptor inhibition attenuates endothelial dysfunction in mice with chronic kidney disease

Kidney International

Volumn 87, Issue 1, 2015, Pages 128-136

  Kajimoto, Hidemi ^a   Kai, Hisashi ^a   Aoki, Hiroki ^b   Uchiwa, Hiroki ^a   Aoki, Yuji ^a   Yasuoka, Suguru ^a   Anegawa, Takahiro ^a   Mishina, Yuji ^c   Suzuki, Akira ^d   Fukumoto, Yoshihiro ^a   Imaizumi, Tsutomu ^a,e  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

^c UNIVERSITY OF MICHIGAN   (United States)

^d KYUSHU UNIVERSITY   (Japan)

^e INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Bone morphogenetic protein receptor activation; chronic kidney disease; Endothelial dysfunction; nitric oxide synthase; phosphataseand tensin homolog; signal transduction

Indexed keywords

6 [4 (1 PIPERAZINYL)PHENYL] 3 (4 QUINOLINYL)PYRAZOLO[1,5 A]PYRIMIDINE; BONE MORPHOGENETIC PROTEIN RECEPTOR 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG RESPONSE; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; MOUSE; NONHUMAN; OSTEOBLAST; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE DEVELOPMENT; C57BL MOUSE; CHRONIC KIDNEY FAILURE; ENDOTHELIUM CELL; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; ENDOTHELIAL CELLS; MICE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE TYPE III; OSTEOGENESIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84920285128     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.223     Document Type: Article

References (27)

1. Keith DS, Nichols GA, Gullion CM et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663.
2. Morris ST, McMurray JJ, Spiers A et al. Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int 2001; 60: 1077-1082.
3. Stam F, van Guldener C, Becker A et al. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: The Hoorn study. J Am Soc Nephrol 2006; 17: 537-545.
4. Blacher J, Guerin AP, Pannier B et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942.
5. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740.
6. Okuno S, Ishimura E, Kitatani K et al. Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis 2007; 49: 417-425.
7. Huang PH, Chen LC, Leu HB et al. Enhanced coronary calcification determined by electron beam CT is strongly related to endothelial dysfunction in patients with suspected coronary artery disease. Chest 2005; 128: 810-815.
8. Wozney JM, Rosen V, Celeste AJ et al. Novel regulators of bone formation: molecular clones and activities. Science 1988; 242: 1528-1534.
9. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to The nucleus. Cell 2003; 113: 685-700.
10. Speer MY, Yang HY, Brabb T et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res 2009; 104: 733-741.
11. Bostrom K, Watson KE, Horn S et al. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993; 91: 1800-1809.
12. Chen NX, Duan D, O'Neill KD et al. The mechanisms of uremic serum-induced expression of bone matrix proteins in bovine vascular smooth muscle cells. Kidney Int 2006; 70: 1046-1053.
13. Yamashita H, ten Dijke P, Huylebroeck D et al. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. J Cell Biol 1995; 130: 217-226.
14. Ebisawa T, Tada K, Kitajima I et al. Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. J Cell Sci 1999; 112(Pt 20): 3519-3527.
15. ten Dijke P, Yamashita H, Sampath TK et al. Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J Biol Chem 1994; 269: 16985-16988.
16. Yu PB, Deng DY, Lai CS et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med 2008; 14: 1363-1369.
17. Derwall M, Malhotra R, Lai CS et al. Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32: 613-622.
18. Kajimoto H, Kai H, Aoki H et al. Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine. Kidney Int 2012; 81: 762-768.
19. Reddi AH. Bone morphogenetic proteins: from basic science to clinical applications. J Bone Joint Surg Am 2001; 83-A (Suppl 1): S1-S6.
20. Osako MK, Nakagami H, Koibuchi N et al. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ Res 2010; 107: 466-475.
21. Hogan BL. Bone morphogenetic proteins in development. Curr Opin Genet Dev 1996; 6: 432-438.
22. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000; 1: 169-178.
23. Fujii M, Takeda K, Imamura T et al. Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol Biol Cell 1999; 10: 3801-3813.
24. Kim CW, Song H, Kumar S et al. Anti-inflammatory and antiatherogenic role of BMP receptor II in endothelial cells. Arterioscler Thromb Vasc Biol 2013; 33: 1350-1359.
25. Waite KA, Eng C. BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels. Hum Mol Genet 2003; 12: 679-684.
26. Mishina Y, Suzuki A, Ueno N et al. Bmpr encodes a type I bone morphogenetic protein receptor that is essential for gastrulation during mouse embryogenesis. Genes Dev 1995; 9: 3027-3037.
27. Hamada K, Sasaki T, Koni PA et al. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 2005; 19: 2054-2065.